The results for this pioneering approach provide the first clinical evidence that modulating immune cell metabolism through targeting PKM2 can translate into meaningful clinical benefit for patients with atopic dermatitis. SYX-5219 was safe and well tolerated over the six-week treatment period.
Healthier Dietary Patterns Associated With Lower Risk. Investigators evaluated 1,324 mother-infant pairs from the Project Viva cohort, assessing maternal diet during early and mid... Prenatal Diet Quality Linked to Lower Risk for Colic Plus Eczema in Infants Maternal nutrition during pregnancy may…
Aclaris Therapeutics Inc. (ACRS) reported positive Phase 1b proof-of-concept results for ATI-052, an investigational antibody designed to target multiple pathways involved in inflammation, with improvements in skin symptoms and lung function observed in separate trials involving patients with atopic dermatitis and…
Delgocitinib poster presentations will include new data from the Phase 3 DELTA TEEN Trial as well as findings from a wide range of health economics and outcomes research and real-world evidence1-9 Multiple poster presentations will feature new data on real-world clinical characteristics…
The “dual-mechanism” anti-IgE antibody CUE-221 has delivered encouraging phase 2 results in chronic spontaneous urticaria. Could it separate from omalizumab and ozureprubart in food allergy? Kuo et al. proposed the CD23 mechanism on the basis of data showing that UB-221, as CUE…
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events. At day 57, ATI-052-treated patients experienced a 45% placebo-adjusted mean improvement from baseline in Eczema Area and Severity Index…
Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma October 27, 2026 8:00 AM EDT William Roberts - Senior Vice President of Corporate Communications & Investor RelationsNeal Walker - Co-Founder, CEO & ChairmanJesse Hall - Chief Medical OfficerRoland Kolbeck - Chief Scientific Officer Hello, and…
Panelists discuss how the COCOON study's advanced dermatologic prophylaxis protocol, including systemic antibiotics and topical treatments, can reduce skin toxicities by 50% in patients receiving amivantamab plus lazertinib therapy. Video content above is prompted by the following: The COCOON clinical trial…
Patients with chronic spontaneous urticaria treated with omalizumab have a lower cardiovascular disease risk than those treated with oral corticosteroids or antihistamines, a real-world study finds. Omalizumab Tied to Lower Heart Disease Risk in Chronic Spontaneous Urticaria Among patients with…
Recipes Beverages and Smoothie Recipes Food Features What Is A Low FODMAP Serving Size? Meal PlannerLow FODMAP Meal Planner! By Deborah Oladapo, on October 15, 2026 This post may contain affiliate links. Please see our disclosure policy for details. What a woman…
Eczema (atopic dermatitis), contact dermatitis and hives: flares and triggers, creams and the new biologic drugs.
An article joins this feed when it matches these terms. Each one is also a search of its own.